MS Ventures is managing investments in a portfolio of 12 companies working in areas relevant to Merck Serono S.A.'s focus in cancer, autoimmune, neurodegenerative and fertility indications, as well as spinouts of non-core assets resulting from the ongoing restructuring of the Merck KGaA (Xetra:MRK) subsidiary. (A) Investment part of Merck KGaA's €30 million ($36.9 million) commitment to fund spinouts; (B) Investment part of €10 million ($14.1 million) Merck Serono Israel Bioincubator Fund; (C) Merck KGaA also gained shares in 2008 as part of the spinout; (D) Merck Serono acquired shares as part of a 2009 collaboration to develop multiple sclerosis candidate ARX424. The partnership is no longer active. Most recent deal